Last $73.50 USD
Change Today 0.00 / 0.00%
Volume 0.0
AZNCF On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 8:10 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2 Kingdom Street

London, W2 6BD

United Kingdom

Phone: 44 20 7604 8000

Fax: 44 20 7604 8151

AstraZeneca PLC, a biopharmaceutical company, is engaged in the discovery, development, manufacturing, and marketing of prescription medicines. The company operates in approximately 100 countries. The company’s primary focus is on three major areas of healthcare, such as cardiovascular (CV) and metabolic disease; oncology; and respiratory, inflammation, and autoimmunity (RIA). It is also active in the infection, neuroscience, and gastrointestinal disease areas. Products CV Disease Marketed Products Atacand1 (candesartan cilexetil) is an angiotensin II antagonist used for the 1st line treatment of hypertension and symptomatic heart failure. Axanum (acetylsalicylic acid (ASA) and esomeprazole) is a fixed-dose combination indicated for prevention of CV events in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers. Brilinta/Brilique (ticagrelor) is an oral antiplatelet for the treatment of acute coronary syndromes. Crestor2 (rosuvastatin calcium) is a statin used for the treatment of dyslipidaemia and hypercholesterolemia. In various markets, it is also indicated to slow the progression of atherosclerosis and to reduce the risk of first CV events. Plendil (felodipine) is a calcium antagonist used for the treatment of hypertension and angina. Seloken/Toprol-XL (metoprolol succinate) is a beta-blocker once-daily tablet used for 24-hour control of hypertension and for use in heart failure and angina. Tenormin (atenolol) is a cardioselective beta-blocker used for hypertension, angina pectoris, and other CV disorders. Zestril3 (lisinopril dihydrate) is an angiotensin-converting enzyme inhibitor used for the treatment of a range of CV diseases, including hypertension. Metabolic Disease Byetta (exenatide injection) is an injectable medicine indicated to improve blood sugar (glucose) control along with diet and exercise in adults with Type 2 diabetes mellitus. Bydureon (exenatide extended release injectable suspension) is an injectable medicine indicated to improve blood sugar (glucose) along with diet and exercise in adults with Type 2 diabetes mellitus. Forxiga/Farxiga (dapagliflozin) is a selective inhibitor of human sodium-glucose co-transporter 2 (SGLT-2 inhibitor) used to improve glycaemic control in adult patients with Type 2 diabetes mellitus. Kombiglyze XR (saxagliptin and metformin XR) combines saxagliptin (Onglyza) and metformin extended release metformin (metformin XR) in a once-a-day tablet for the treatment of Type 2 diabetes mellitus. Komboglyze (saxagliptin and metformin HCl) combines saxagliptin (Onglyza) and metformin immediate release (metformin IR) in a twice-daily tablet for the treatment of Type 2 diabetes mellitus. Onglyza (saxagliptin) is an oral dipeptidyl peptidase 4 (DPP-4) inhibitor used for the treatment of Type 2 diabetes mellitus. Symlin (pramlintide acetate) is an injected amylin analogue for the treatment of Type 1 and Type 2 diabetes mellitus in patients with inadequate glycaemic control on mealtime insulin. Xigduo (dapagliflozin and metformin hydrochloride) combines dapagliflozin (Forxiga), an SGLT-2 inhibitor, and metformin hydrochloride, in a twice-daily tablet to improve glycaemic control in adult patients with Type 2 diabetes mellitus, who are inadequately controlled by metformin alone. Oncology Marketed Products Arimidex (anastrozole) is an aromatase inhibitor used for the treatment of breast cancer. Caprelsa (vandetanib) is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease. Casodex (bicalutamide) is an anti-androgen therapy used for the treatment of prostate cancer. Faslodex (fulvestrant) is an injectable estrogen receptor antagonist used for the treatment of hormone receptor-positive advanced breast cancer for post-menopausal women whose disease has progressed following treatment with prior endocrine therapy. Iressa (gefitinib) is an epidermal growth factor receptor-tyrosine kinase (EGFR-TK) inhibitor that acts to block signals f

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZNCF:US $73.50 USD 0.00

AZNCF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.28 USD -0.32
Amgen Inc $139.38 USD +0.69
Biogen Idec Inc $343.04 USD +1.80
Bristol-Myers Squibb Co $50.65 USD +0.11
Novo Nordisk A/S kr259.00 DKK +1.00
View Industry Companies
 

Industry Analysis

AZNCF

Industry Average

Valuation AZNCF Industry Range
Price/Earnings 47.2x
Price/Sales 3.7x
Price/Book 4.3x
Price/Cash Flow 47.3x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.